The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies
Open accessAbstract
Importance: Recent meta-analyses of randomized clinical trials (RCTs) comparing clozapine with nonclozapine second-generation antipsychotics (NC-SGAs) in schizophrenia have challenged clozapine's superiority in treatment-resistant patients. However, patients in RCTs are not necessarily generalizable to those in clinical practice. Objective: To conduct a systematic review and meta-analysis to compare various outcomes of clozapine vs oral NC-SGAs in cohort studies. Data Sources: Systematic literature search in PubMed, PsycINFO, and CINAHL without language restriction from database inception until December 17, 2018. Study Selection: Nonrandomized cohort studies reporting effectiveness and/or safety outcomes comparing clozapine with NC-SGAs in schizophrenia or schizoaffective disorder. Data Extraction and Synthesis: Independent investigators assessed studies and extracted data. Using a random-effects model, the study calculated risk ratio (RR) unadjusted for covariates and follow-up duration, number needed to treat/number needed to harm (NNT/NNH) for dichotomous data, and standardized mean difference (SMD) or mean difference (MD) for continuous data. Main Outcomes and Measures: Coprimary outcomes were hospitalization and all-cause discontinuation. Secondary outcomes included all effectiveness and safety outcomes reported in at least 3 analyzable studies. Results: Of 8446 hits, 68 articles from 63 individual cohort studies (n = 109 341) (60.3% male; mean [SD] age of 38.8 [6.5] years, illness duration of 11.0 [5.1] years, and study duration of 19.1 [23.3] months) were meta-analyzed. Compared with NC-SGAs, despite greater illness severity (17 studies [n = 38 766]; Hedges g, 0.222; 95% CI, 0.013-0.430; P = .04), clozapine was significantly associated with lower hospitalization risk (19 studies [n = 49 453]; RR, 0.817; 95% CI, 0.725-0.920; P = .001; NNT, 18; 95% CI, 12-40) and all-cause discontinuation (16 studies [n = 56 368]; RR, 0.732; 95% CI, 0.639-0.838; P < .001; NNT, 8; 95% CI, 6-12). Associations were statistically significant for comparisons with quetiapine fumarate and aripiprazole regarding hospitalization and all NC-SGAs, except aripiprazole, for all-cause discontinuation. Clozapine was also significantly associated with better outcomes regarding overall symptoms (SMD, -0.302; 95% CI, -0.572 to -0.032; P = .03) and Clinical Global Impressions scale severity (SMD, -1.182; 95% CI, -2.243 to -0.122; P = .03). Clozapine was significantly associated with increases in body weight (MD, 1.70; 95% CI, 0.31-3.08 kg; P = .02), body mass index (MD, 0.96; 95% CI, 0.24-1.68; P = .009), and type 2 diabetes (RR, 1.777; 95% CI, 1.229-2.570; P = .002; NNH, 27; 95% CI, 13-90). Conclusions and Relevance: In cohort studies, despite more severely ill patients being treated with clozapine, use of clozapine was associated with better key efficacy outcomes and higher cardiometabolic-related risk outcomes vs NC-SGAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Self-citationMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Self-citationGalletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Self-citationPatient Preference and Adherence
(2020) · doi:10.2147/ppa · Cited by 731
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Self-citationSiskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427
Self-citationKishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
Self-citationSiskind, D., Siskind, V., & Kisely, S. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717718167 · Cited by 391
Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 307
Self-citationSamara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262
Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246
Self-citationNielsen, J., Correll, C. U., Manu, P., & Kane, J. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08064 · Cited by 232
Self-citationAntipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186
Self-citationStroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030332 · Cited by 173
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone
Green, A. I., Burgess, E. S., Dawson, R., Zimmet, S. V., & Strous, R. D. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00231-1 · Cited by 146
The impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.01.012 · Cited by 131
Self-citationHaro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 126
Human Psychopharmacology: Clinical and Experimental
(2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(issn)1099-1077 · Cited by 122
The Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98
Self-citationRehospitalization Rates of Patients Recently Discharged on a Regimen of Risperidone or Clozapine
Conley, R. R., Love, R. C., Kelly, D. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.863 · Cited by 92
Adherence to Atypical Antipsychotic Treatment Among Newly Treated Patients
Cooper, D., Moisan, J., & Grégoire, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0601 · Cited by 88
Weitoft, G. R., Berglund, M., Lindström, E., Nilsson, M., Salmi, P., & Rosén, M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3567 · Cited by 80
Vanasse, A., Blais, L., Courteau, J., Cohen, A. A., Roberge, P., Larouche, A., Grignon, S., Fleury, M., LESAGE, A. D., Demers, M., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12621 · Cited by 78
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia
Sharma, T., Hughes, C., Soni, W., & Kumari, V. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1506-y · Cited by 73
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Lacro, J. P., Dolder, C. R., & Peng, X. (2008) · Patient Preference and Adherence · doi:10.2147/ppa.s2940 · Cited by 64
Rehospitalization Risk with Second-Generation and Depot Antipsychotics
Conley, R. R., Kelly, D. L., Love, R. C., & McMahon, R. P. (2003) · Annals of Clinical Psychiatry · doi:10.1023/a:1023276509470 · Cited by 50
de Castro, A. P. W., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300004 · Cited by 43
Comparing the Use and Discontinuation of Antipsychotics in Clinical Practice
Taylor, M., Shajahan, P. M., & Lawrie, S. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0210 · Cited by 43
Velligan, D. I., Carroll, C., Lage, M. J., & Fairman, K. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300085 · Cited by 35
Bitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., Bacskai, M., Láng, Z., Gyáni, G., & Czobor, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.003 · Cited by 34
Herceg, M., Jukić, V., Vidović, D., Erdeljić, V., Ćelić, I., Kozumplik, O., Bagarić, D., & Radić, M. S. (2008) · Croatian Medical Journal · doi:10.3325/cmj.2008.2.215 · Cited by 34
Werneck, A. P., Hallak, J. E. C., Nakano, E. Y., & Elkis, H. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.04.004 · Cited by 33
Guo, X., Fang, M., Zhai, J., Wang, B., Wang, C., Hu, B., Sun, X., Lv, L., Lu, Z., Ma, C., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2242-3 · Cited by 30
Pragmatic and Observational Research
(2020) · Pragmatic and Observational Research · doi:10.2147/por · Cited by 29
Kim, J. H., Kim, D., & Marder, S. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.009 · Cited by 27
Lin, C., Lin, S., Chen, M., & Wang, S.-Y. (2006) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(09)70254-0 · Cited by 26
Williams, R., Kopala, L. C., MALLA, A. K., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00757.x · Cited by 26
The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire
Hodgson, R. E., Belgamwar, R. B., Al-tawarah, Y., & MacKenzie, G. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.669 · Cited by 23
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia
Buoli, M., Kahn, R. S., Serati, M., Altamura, A. C., & Cahn, W. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2542 · Cited by 22
Karagianis, J. L., Williams, R. L., Davis, L., Procyshyn, R. M., Monga, N., Hanley, J. A., Chandrasena, R. D., Thakur, A., & Dickson, R. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903102966 · Cited by 16
Nyakyoma, K., & Morriss, R. K. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4290 · Cited by 8
Schizophrenia Outpatient Health Outcomes study: twelve-month findings
Novick, D., Ascher-Svanum, H., Haro, J. M., Bertsch, J., & Takahashi, M. (2012) · Pragmatic and Observational Research · doi:10.2147/por.s26552 · Cited by 6
Treuer, T., Martényi, F., Şaylan, M., & Dyachkova, Y. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02331.x · Cited by 6
Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M., Sutterland, A. L., Correll, C. U., & de Haan, L. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby015.215 · Cited by 5
Self-citation
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
de Leon, J., Schoretsanitis, G., Smith, R. L., Molden, E., Solismaa, A., Seppälä, N., Kopeček, M., Švancer, P., Olmos, I., Ricciardi, C., et al. (2022) · Pharmacopsychiatry · doi:10.1055/a-1625-6388 · Cited by 275
Self-citation
Metadata
- Authors
- Masuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2019-10-01
- Volume
- 76
- Issue
- 10
- Pages
- 1052
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2965042655
- Cited by
- 319
- References
- 63
- FWCI
- 38.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.